-
Characterization of MJFF Alpha-Synuclein Filament-specific Antibodies
… When the procedures have been optimized, extracts from normal control and Parkinson’s brain tissue will be … subsequent microscopical analyses of human brain slices from normal control and Parkinson’s patients prepared under …
-
CISD1 (mitoNEET) as a Mitochondrial Drug Target in Parkinson’s Disease
… normal mitochondrial function. Elimination of mitoNEET from brain cells may show the same mitochondrial dysfunction … to Diagnosis/Treatment of Parkinson’s Disease: The results from this study will validate the usefulness of mitoNEET as …
-
Cutaneous Alpha-Synuclein Deposition — A Biomarker in Parkinson’s Disease
… blood vessels in tissue obtained (1) by skin punch biopsy from clinically diagnosed PD subjects and controls and (2) from post-mortem skin tissue of pathologically confirmed PD …
-
Fluorescence Fluctuation Spectroscopy Assays to Monitor the Activity of LRRK2
… activity based on its properties using the fluorescence from cells containing wild-type (not mutated) LRRK2, the Parkinson’s disease form G2019S and an inactive form. From this, we will test our outline of activity by measuring …
-
Michael Takes on the Big Questions in His Next Book
March 6, 2020
… is busy writing his fourth book, due out November 17 from Flatiron Books. Over at People.com, Sam Gilette got the … on the big questions. He’s never been one to shy away from a challenge . “Only Michael J. Fox could write about …
-
Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease
… This grant builds upon the research from a prior grant: 5-alpha-reductase Inhibition for the … neurosteroid(s) is responsible for the observed protection from dyskinesia. They found that inhibiting this enzyme …